pharma news - Latest News, Analysis, Opinion

In India, the Danish drugmaker Novo Nordisk is the market leader and presently meets over 60 per cent of the country’s insulin supply. Speaking to BW Businessworld in an exclusive interaction, John C. Dawber, CVP and MD, Global Business Services talks about the company’s GLP1 growth story, the market of obesity drugs and their safety profile, building capacities and the company's future ambitions in India

Glenmark Slashes Cost Of Breast Cancer Drug Trastuzumab In India

Glenmark Pharmaceuticals, the global pharmaceutical company on Thursday restructured the price of Trastuzumab drug indicated for HER2‐positive breast cancer. A 440 mg vial of Trumab will be priced at Rs 15,749, which makes it the most affordable option available currently in the country, the company said in a statement

Zydus Gets Nil Observations On USFDA Inspection, Receives Nod For Two Drugs

On Tuesday, Zydus Lifesciences in an exchange filing revealed that the group’s injectables manufacturing facility at Zydus Biotech Park in Changodar, Ahmedabad, underwent USFDA inspection from 05 June to 13 June 2023 with the cGMP inspection concluded with nil observations

Biocon Investing Heavily In Peptides, Potent Oncology APIs: MD & CEO, Siddharth Mittal

Biocon’s MD and CEO, Siddharth Mittal in a post-annual results interaction with BW Healthcare World stated that, “As we move forward, we see a huge potential in peptides. It is a growing segment where the big shift is being seen with companies like Novo Nordisk or Eli Lilly moving their focus from insulins to GLP1 drugs and what used to be USD 20-30 billion insulin market is now actually projected to be over USD 100 billion GLP1 market"

Biocon's Net Profits Soar In Q4FY23 By 31% YoY, Revenues Up By 58.6%

Bangalore-based pharmaceutical company Biocon on Tuesday announced its consolidated financial results for the fourth quarter that ended 31st March 2023, the company registered a 58.6 per cent rise in its consolidated revenues from operations year on year. The company's consolidated revenue for the March quarter stood at Rs 3,928 crores against Rs 2,476 crores in the same quarter last year

Divi's Labs PAT Slumps By 64.2% In Q4FY23

Divi's Laboratories on Saturday announced its earnings for the fourth quarter and full year FY23. The company posted a drop in its net profits by 64.2 per cent year on year (YoY) in the March quarter to Rs 320 crores down from 894 crores in the same quarter of the previous year

India Considering A Policy Change In Pharma After Cough Syrup Deaths

Health Minister Mansukh Mandaviya and federal and state regulators attended the session in February, according to a statement from the health ministry that did not mention cough syrups

Gland Pharma's Net Profits Tank By 72.2% YoY In Q4FY23

Gland Pharma on Thursday announced its earnings for the fourth quarter and full year FY23. The company's revenue recorded a slump in Q4FY23 by 29.4 per cent year on year (YoY) to be recorded at Rs 824 crore and by 16.6 per cent for FY23 to Rs 3,856 crore compared with Rs 1,168 crore in Q4FY22 and Rs 4,624 in FY22 respectively

Q4 Results: Cipla's Net Profit Rises By 40% YoY, Consolidated Revenue At 5,739 Cr

Cipla Limited, the Indian pharmaceutical major headquartered in Mumbai has reported its earnings for the quarter that ended on 31st March 2023, the Indian pharma giant has registered a rise of 8.3 per cent in its consolidated revenue to be recorded at Rs 5,739 crores in the Quarter Four of Financial Year 2022(Q4FY23) up from Rs 5,260 crores in the corresponding quarter last year

India’s Diplomatic Effort To Protect Drug Exports After Deaths From Substandard Drugs

Indian officials are in contact with foreign authorities and have held meetings in Africa to ensure its drug exports do not suffer, the government said on Wednesday, after Indian-made cough syrups were linked to deaths in Gambia and Uzbekistan

Vikas Vij To Be The New CEO Of IOL Chemicals And Pharmaceuticals

IOL Chemicals and Pharmaceuticals Limited (IOL), a manufacturer of pharmaceutical (APIs) and specialty chemicals, has appointed Vikas Vij as the new Chief Executive Officer, with effect from 3rd April 2023 taking over from Dr Sanjay Chaturvedi who served as the company CEO from 2021 onwards

Centre Revokes Licenses Of 18 Pharma Companies For Manufacturing Spurious Drugs: Report

The government of India has canceled the licenses of 18 pharma companies for manufacturing of spurious medicines following an inspection by the Drugs Controller General of India (DCGI) on 76 companies across 20 States

Hurting Generic Industry Compelling Pharma To Spend More On R&D

Industry experts contend that largely the research budgets of the top firms have remained flattish in the last two to three years on account of Covid, but the scenario might be changing for some select firms like Sun Pharmaceuticals, Dr Reddy’s Labs, Zydus Lifesciences, Cipla and Biocon Biologics among others due a hurting generic pharma industry

India Must Focus On Biopharmaceuticals To Feed The Growth Engine: Kiran Mazumdar Shaw